ABSTRACT A single deep inspiration (DI) is commonly followed by transient airflow obstruction in asthmatic patients. In some patients, however, DI results in a sustained response which suggests that more than one mechanism may be responsible. We have studied the characteristics of the response to repeated DI, and their modification by various pharmacological agents, by measuring specific airway resistance (sRaw) in ten subjects who showed reproducible and consistent increases in sRaw after DI. 
Bronchoconstrictor effects of deep inspirations (DI) in asthmatic patients have been reported by several authors (Herxheimer, 1946; Dubois et al, 1956; Gimeno et al, 1972; Messerli et al, 1975; Roncoroni et al, 1975; Fish et al, 1977) and related to the bronchial hyperreactivity described in asthma (Simonsson et al, 1967) . The prevalence of such a reaction remains ill-defined. We have previously observed , however, that brief bronchoconstriction is induced by DI in most asthmatic patients though in some, DI results in sustained effects.
The purposes of the present study were (a) to define the two types of response to DI; (b) to investigate the influence of repeating DI on these responses, since maximal ventilatory manoeuvres are required during routine measurement of pulmonary function and are repeated at variable intervals, especially during bronchial provocation tests; and (c) to gain some insight into the different mechanisms affected by observing the effects of various pharmacological agents on the response to repeated DI.
Methods
Thoracic gas volume (Vtg) and specific airway resistance (sRaw) were measured in a pressure body plethysmograph according to the technique of Dubois et al (1956 During additional sessions one or other of the following agents was administered by inhalation before the DI manoeuvres: a beta-adrenergic stimulant (BAS, salbutamol aerosol, 0-2-0-4 mg); an anticholinergic agent (AC, ipratropium bromide aerosol: Sch 1000 0-4-2 mg) (Engelhardt and Klupp, 1975) ; or disodium cromoglycate (DSCG 100 mg), a drug known to prevent mediator release from mast-cells. The aerosols were taken during a submaximal inspiration from FRC, and followed by a four-second breath-hold. DSCG powder was administered by a compressed-air nebuliser (Aerosolan Gauthier) and inhaled by the subject breathing through a two-way valve until completion. The subjects were then asked to rest five minutes after BAS, 15 minutes after AC, and 20 minutes after DSCG.
Altholugh rather high doses of AC were administered, we observed few side effects except inhibition of the salivary secretion.
Inhibition 
Results

TYPES OF RESPONSES
We selected from the 34 subjects 10 responders (table 1) who showed a consistent increase in sRaw (larger than 40% of the initial value) after DI when examined on different occasions. Of the 24 remaining subjects, the responses were weaker in 13 and insignificant in 11. Even in the responders variations were observed within subjects, and for a given subject from day to day, as in patient 3 ( fig 2a) , however, the responses decreased progressively with repeated DI.
In another subject (patient 7, fig 3a) (three subjects).
In the two subjects with type B reactions after the persistent rise in sRaw induced by the initial DI, subsequent DI produced further increase in sRaw (fig 4a) and a simultaneous increase in FRC (table 2). The repetition of DI without a time interval induced a faster rise in sRaw in subject 9. In contrast repeated DI without a time interval seemed to postpone the onset of increase in sRaw in subject 10 (fig 4b) .
ADMINISTRATION OF PHARMACOLOGICAL AGENTS
Inhalation of a beta-adrenergic stimulant (BAS) completely prevented the responses to DI in nine of the 10 cases (table 2, figs lc, 2c, 3c). In contrast the effect of DI was reduced by subsequent administration of BAS (figs 3c, 4b) in all cases.
The anticholinergic agent ipratropium (AC, Sch 1000) largely prevented (65% to 100%) the reactions to DI in six of the eight subjects with type A response. Both BAS and AC decreased the baseline sRaw (figs lc, 2c, 3c, 4c) and FRC. In subject 7 (fig 3c) AC decreased the baseline sRaw, with little influence on the response to DI itself. Although large amounts of AC did not influence the peak response to DI in subject 3 (fig 2) , inhibition was obtained by an additional intravenous injection of atropine sulphate (0-5 mg). In type B reactions the responses to DI were inhibited by AC in subject 9 ( Messerli et al (1975) . We find the occurrence of such reactions to be far less frequent than that of type A. This can be approximated to 1% of an overall adult asthmatic population in Gimeno's publication.
Repeated DI produced no cumulative effect in patients with type A reactions. It is interesting to compare this finding with the observation of Fish et al (1977) that after mathacholine-induced bronchoconstriction DI was followed by small and variable changes in airway conductance, in contrast to the fall produced by DI in the control state. Although these data suggest a limited influence of repeated DI, we have previously shown (Orehek et al, 1975a ) that the overall effect results in a potentiation of the bronchial response during provocation tests. Moreover, repeating DI, and particularly when this was done without a time interval, produced in some patients a reduction in the magnitude of the response. In consequence, the time interval between repeated respiratory manoeuvres will unpredictably modify the influence of such manoeuvres on respiratory function testing.
In the few cases with type B reactions the cumulative responses to repeated DI could lead to false conclusions during provocation tests: increasing responses may be due to the manoeuvres rather than to the administered bronchoconstrictor substance.
Our study confirms previous work (Simonsson et al, 1967; Gayrard et al, 1975) showing that the increase in sRaw after DI is due to bronchoconstriction. This response exhibited the clinical and functional features of an attack of asthma. Moreover, the response to DI could be inhibited by bronchodilator agents, thus showing its muscular origin; the inhibitory influence of BAS rules out other possible causes of acute bronchial obstruction after DI, such as sudden glandular secretion, tissue oedema, or a decrease in lung elastic recoil and in airway calibre resulting from sudden inflation (Finucane and Colebatch, 1969 Mechanisms of the bronchoconstrictor efjects of deep inspiration in asthmatic patients by bronchial stretching during DI of the irritant receptors (Mills et al, 1975) , possibly "sensitised" in asthmatic subjects (Simonsson et al, 1967) . This hypothesis was supported by the inhibitory effects of an anticholinergic agent already reported (Widdicombe, 1974) , although the dose of AC inhaled in our experiment can be considered as maximal (Engelhardt and Klupp, 1975 Messerli et al (1975) .
Cholinergic pathways are also probably affected in type B responses that were reduced by AC in one of the two subjects. Different mechanisms, however, may account for the protective effect of AC: firstly, a decrease in vagal tone will alter the bronchial reactivity to various stimuli (Widdicombe, 1974) , and, secondly, an inhibitory effect by AC towards mediators (Austen and Orange, 1975; Orehek et al, 1975b) . Similarly, a beta-adrenergic agonist may inhibit mediator release (Austen and Orange, 1975) . Thus BAS provides another mechanism of inhibition of the type B responses to DI.
In subject 10 repeated DI produced no immediate onset of bronchoconstriction and AC did not prevent subsequent bronchoconstrictions. Thus this subject possibly had no vagal contribution in his response to DI. The mechanism of an immediate bronchodilator effect of DSCG in this case remains conjectural: it could be due either to a direct effect (Lavin et al, 1976 ) on smooth muscle, or to blockade of mediators that were being continuously released.
Knowing the response of a given asthmatic patient to maximal respiratory movements has some practical implications. In the clinical management of such patients one must avoid respiratory exercises and use appropriate protective agents. 
